There are a number of so-called undruggable targets that have eluded attempts to find potent small-molecule compounds to affect their expression. One such protein is the oncogenic transcription factor Myc. Now, scientists from McGill University have developed a screen that could detect compounds that indirectly affect Myc expression. Read More
Bio-Path Holdings Inc., of Houston, said it closed its registered direct offering, which sold 712,910 shares at $25.95 each, for gross proceeds of approximately $18.5 million. The company intends to use the net proceeds for working capital and general corporate purposes. Read More
Outlook Therapeutics Inc., of Cranbury, N.J., approved a 1-for-8 reverse stock split, effective March 18. The number of shares of common stock issued and outstanding will be reduced from approximately 94.1 million to approximately 11.8 million. The number of authorized shares won't change. Read More
HONG KONG – Seoul, South Korea-based SN Bioscience Inc. has developed a drug delivery technology to make injecting antitumor drugs into human bodies possible. Two months after it secured KRW5 billion (US$4.4 million) from South Korea's energy and chemical giant, OCI Co., in a series A financing, the firm is expecting another investment of $3.5 million in the coming weeks. The funding will help it spearhead the development of its core asset, SNB-101, to treat pancreatic cancer. Read More
Redpin Therapeutics Inc., a New York-based preclinical gene therapy startup leveraging a chemogenetics approach to hard-to-treat CNS diseases, has highlighted a new paper in Science detailing the ion channel-based platform behind its nascent pipeline. The approach, the rights to which Redpin exclusively licensed from the Howard Hughes Medical Institute (HHMI), enables targeted cell activation or inhibition that can be controlled by low doses of the anti-smoking drug Chantix (varenicline), it said. Read More
The prospects of an oral taxane chemotherapy – providing similar efficacy to intravenous (I.V.) with a better toxicity profile – have drawn players to the field that include Odonate Therapeutics Inc. and Athenex Inc., the latter with a phase III trial fully enrolled and the former with a late-stage experiment expected to finish sign-ups in the second half of this year. Read More
Record-breaking financings in 2018 trickled down to almost every therapeutic area, showing in many cases double- and triple-digit percent increases of funds flowing into biopharma companies working on everything from cell and gene therapies to cancer immunotherapies and microbiome therapeutics. Read More
